Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report

Overview of attention for article published in OncoTargets and therapy, December 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 1 news story.

G724S确实是奥希替尼耐药突变，比较罕见，也说明本次检测为患者找到了具体的耐药机制。那么针对该突变，有什么治疗指导呢？让我们一起引经据典！现阶段，三代EGFR-TKI凭借着其优异的疗效和安全性，树立了EGFR突变晚期NSCLC一线治疗的新标准，并被国内外…